CTLA4 Antikörper (FITC)
Kurzübersicht für CTLA4 Antikörper (FITC) (ABIN951193)
Target
Alle CTLA4 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Spezifität
- Recognizes Human CTLA-4 (CD152).
-
Aufreinigung
- Affinity Chromatography on Protein G
-
Immunogen
- Activated T cells Donor: Balb/c mouse Fusion Partner: SP 2/0 myeloma
-
Isotyp
- IgG2a
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 0.1 mg/mL
-
Buffer
- PBS containing 0.02 % Sodium Azide as preservative and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/mL.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freezing and thawing.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))
-
Andere Bezeichnung
- CD152 / CTLA4
-
Hintergrund
- Human CTLA-4 (also known as Cytotoxic T lymphocyte-associated antigen-4, CD152) is a structural homologue of T cell co-stimulatory receptor CD28. CTLA-4 binds to the same ligands (CD80 and CD86) as CD28 but with much higher avidity. It is expressed at very low levels on the cell surface of activated T cells, and is found primarily in the post-Golgi or endosomal compartments of the cell. There is a high degree of overall homology between human and mouse CTLA-4 (>70 % ), and the cytoplasmic domains of the human, mouse and rabbit sequences are completely conserved. CD152 antibodies have shown both stimulatory and negative regulatory roles in functional experiments.Synonyms: CTLA-4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4
-
Gen-ID
- 1493
-
NCBI Accession
- NP_001032720
-
UniProt
- P16410
-
Pathways
- Cancer Immune Checkpoints
Target
-